Lipid tucaresol as an adjuvant for methamphetamine vaccine development

被引：23
作者：
Collins, K. C. [1 ,2 ,3 ]
Schlosburg, J. E. [1 ,2 ,3 ,4 ]
Lockner, J. W. [1 ,2 ,3 ]
Bremer, P. T. [1 ,2 ,3 ]
Ellis, B. A. [1 ,2 ,3 ]
Janda, K. D. [1 ,2 ,3 ]
机构：
[1] Scripps Res Inst, Dept Chem, Skaggs Inst Chem Biol, WIRM, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Immunol, Skaggs Inst Chem Biol, WIRM, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Microbial Sci, Skaggs Inst Chem Biol, WIRM, La Jolla, CA 92037 USA
[4] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA
来源：
CHEMICAL COMMUNICATIONS | 2014年 / 50卷 / 31期
关键词：
IMMUNIZATION; LIPOSOMES; HAPTEN; SYSTEM; IMPACT;
D O I：
10.1039/c4cc00682h
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The immunopotentiator tucaresol was modified for incorporation into liposomes, where it was found to be a superior adjuvant to MPLA for vaccination against methamphetamine.
引用
收藏
页码：4079 / 4081
页数：3
相关论文
共 50 条
  • [31] Cell Recruitment and Cytokines in Skin Mice Sensitized with the Vaccine Adjuvants: Saponin, Incomplete Freund's Adjuvant, and Monophosphoryl Lipid A
    Vitoriano-Souza, Juliana
    Moreira, Nadia das Dores
    Teixeira-Carvalho, Andrea
    Carneiro, Claudia Martins
    Mathias Siqueira, Fernando Augusto
    de Abreu Vieira, Paula Melo
    Giunchetti, Rodolfo Cordeiro
    de Lima Moura, Sandra Aparecida
    Fujiwara, Ricardo Toshio
    Melo, Maria Norma
    Reis, Alexandre Barbosa
    PLOS ONE, 2012, 7 (07):
  • [32] Syphilis vaccine development: Aligning vaccine design with manufacturing requirements
    Waugh, Sean
    Cameron, Caroline E.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [33] Synthesis and biological evaluation of a lipopeptide-based methamphetamine vaccine
    Liao, Fan
    Wang, Hanxuan
    Dao, Yuankun
    Yuan, Kai
    Lu, Jiazhen
    Shi, Jie
    Han, Ying
    Dong, Suwei
    Lu, Lin
    CHINESE CHEMICAL LETTERS, 2021, 32 (04) : 1575 - 1579
  • [34] Liposomal delivery system/adjuvant for tuberculosis vaccine
    Moradi, Melika
    Vahedi, Farzaneh
    Abbassioun, Arian
    Shahi, Arash Ramezanpour
    Sholeh, Mohammad
    Taheri-Anganeh, Mortaza
    Dargahi, Zahra
    Ghanavati, Roya
    Khatami, Seyyed Hossein
    Movahedpour, Ahmad
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (06)
  • [35] Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine
    Gong, Yanfeng
    Tao, Liming
    Wang, Fucai
    Liu, Wei
    Jing, Lei
    Liu, Dongsheng
    Hu, Sijun
    Xie, Yong
    Zhou, Nanjin
    MOLECULAR MEDICINE REPORTS, 2015, 12 (03) : 4123 - 4132
  • [36] Linking vaccine adjuvant mechanisms of action to function
    Ben-Akiva, Elana
    Chapman, Asheley
    Mao, Tianyang
    Irvine, Darrell J.
    SCIENCE IMMUNOLOGY, 2025, 10 (104)
  • [37] A clinically applicable adjuvant for an atherosclerosis vaccine in mice
    Kobiyama, Kouji
    Vassallo, Melanie
    Mitzi, Jessica
    Winkels, Holger
    Pei, Hong
    Kimura, Takayuki
    Miller, Jacqueline
    Wolf, Dennis
    Ley, Klaus
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 (09) : 1580 - 1587
  • [38] Recent advances on chitosan as an adjuvant for vaccine delivery
    Dmour, Isra
    Islam, Nazrul
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2022, 200 : 498 - 519
  • [39] THE IMMUNOLOGICAL ADJUVANT AND VACCINE CARRIER PROPERTIES OF LIPOSOMES
    GREGORIADIS, G
    JOURNAL OF DRUG TARGETING, 1994, 2 (05) : 351 - 356
  • [40] A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens
    Swaminathan, Gokul
    Thoryk, Elizabeth A.
    Cox, Kara S.
    Meschino, Steven
    Dubey, Sheri A.
    Vora, Kalpit A.
    Celano, Robert
    Gindy, Marian
    Casimiro, Danilo R.
    Bett, Andrew J.
    VACCINE, 2016, 34 (01) : 110 - 119
12345